查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468363

杜氏肌肉營養不良症藥物市場按產品類型（皮質類固醇、疼痛管理藥物）、治療方法（突變抑制、外顯子跳躍、類固醇治療）、最終用戶（醫院、診所、家庭護理機構）和地區 2024-2032

Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球杜氏肌肉營養不良症藥物市場規模達23億美元。杜氏肌肉營養不良症在大眾中患病率不斷上升、新產品批准和上市數量不斷增加、政府提供良好報銷政策的有利舉措以及推廣針對特定目標的治療方法，是推動市場發展的一些關鍵因素。

杜氏肌肉營養不良 (DMD) 藥物用於治療嚴重的 X 連鎖遺傳性疾病，即進行性肌肉營養不良，主要影響男性群體，很少影響女性。這種疾病的症狀包括行走、站立和坐立困難以及言語困難，這可能導致骨骼肌和心肌進行性無力和喪失，也稱為萎縮。 DMD 藥物透過針對心臟和骨骼肌來增強患者的心肺功能。肌營養不良蛋白是維持肌肉完整性的關鍵蛋白質，其缺失或異常會導致 DMD。因此，大多數治療 DMD 的藥物都是基於肌肉營養不良蛋白的。 DMD 的其他一些主要治療策略還包括與特定突變相關的基因療法，這些突變可恢復肌營養不良蛋白的產生、膜穩定或補償蛋白的上調，以及減少發炎級聯和/或增強肌肉再生。

杜氏肌肉營養不良症藥物市場趨勢：

主要製造商批准和推出的新產品數量不斷增加是推動市場成長的重要因素。這可以歸因於杜氏肌肉營養不良症在群眾中的發生率不斷上升。與此一致的是，臨床試驗的大幅增加以及強大的產品線的存在正在為市場提供動力。此外，由於診斷技術的不斷創新，突變特異性療法的出現也對市場產生了積極影響。除此之外，針對嬰兒、女性和非行走患者等服務不足類別的 DMD 準確診斷和治療的廣泛研發 (R&D) 活動正在推動市場發展。然而，藥物臨床療效檢查標準化程序的缺乏、診斷和預測的延遲以及基因治療成本的上升正在成為市場成長的限制因素。相反，有利的政府措施提供了良好的報銷政策，並推廣針對特定目標的治療，正在促進市場成長。在市場上創造利潤豐厚的成長機會的其他一些因素包括快速城市化、醫療基礎設施的改善、產品高階化的趨勢以及大眾可支配收入的增加。

本報告回答的關鍵問題

  • 全球杜氏肌肉營養不良症藥物市場有多大？
  • 2024-2032年全球杜氏肌肉營養不良症藥物市場的預期成長率是多少？
  • 推動全球杜氏肌肉營養不良症藥物市場的關鍵因素是什麼？
  • COVID-19 對全球杜氏肌肉營養不良症藥物市場有何影響？
  • 根據產品類型，全球杜氏肌肉營養不良症藥物市場的細分如何？
  • 根據治療方法，全球杜氏肌肉營養不良症藥物市場的詳細情形如何？
  • 基於最終用戶，全球杜氏肌肉營養不良症藥物市場的細分如何？
  • 全球杜氏肌肉營養不良症藥物市場的關鍵區域有哪些？
  • 全球杜氏肌肉營養不良症藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球杜氏肌肉營養不良症藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品類型

  • 皮質類固醇
    • 市場走向
    • 關鍵環節
      • 潑尼松龍
      • 強的松
      • 地夫可特
    • 市場預測
  • 疼痛管理藥物
    • 市場走向
    • 市場預測

第 7 章：市場區隔：透過治療方法

  • 突變抑制
    • 市場走向
    • 市場預測
  • 外顯子跳躍
    • 市場走向
    • 市場預測
  • 類固醇治療
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 診所
    • 市場走向
    • 市場預測
  • 家庭護理設置
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • FibroGen Inc.
    • Italfarmaco SpA
    • NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
    • PTC Therapeutics Inc.
    • Santhera Pharmaceuticals
    • Sarepta Therapeutics Inc.
Product Code: SR112024A6715

The global Duchenne muscular dystrophy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 9.96% during 2024-2032. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.

Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

Duchenne Muscular Dystrophy Drugs Market Trends:

The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, therapeutic approach, and end user.

Product Type Insights:

Corticosteroids

Prednisolone

Prednisone

Deflazacort

Pain Management Drugs

The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone, and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.

Therapeutic Approach Insights:

Mutation Suppression

Exon Skipping

Steroid Therapy

The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.

End User Insights:

Hospitals

Clinics

Home Care Settings

A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Duchenne muscular dystrophy drugs market?
  • 2. What is the expected growth rate of the global Duchenne muscular dystrophy drugs market during 2024-2032?
  • 3. What are the key factors driving the global Duchenne muscular dystrophy drugs market?
  • 4. What has been the impact of COVID-19 on the global Duchenne muscular dystrophy drugs market?
  • 5. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the product type?
  • 6. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
  • 7. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the end user?
  • 8. What are the key regions in the global Duchenne muscular dystrophy drugs market?
  • 9. Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Duchenne Muscular Dystrophy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Prednisolone
      • 6.1.2.2 Prednisone
      • 6.1.2.3 Deflazacort
    • 6.1.3 Market Forecast
  • 6.2 Pain Management Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Approach

  • 7.1 Mutation Suppression
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Exon Skipping
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Steroid Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Home Care Settings
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 FibroGen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Italfarmaco S.p.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 PTC Therapeutics Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Santhera Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Sarepta Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2023
  • Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2023
  • Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million US$), 2024-2032
  • Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
  • Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players